Combining <scp>γ‐GT</scp> , <scp>PIVKA‐II</scp> , and <scp>AFP</scp> to predict long‐term prognosis in patients with hepatocellular carcinoma after hepatectomy-Reference-Cited by-同舟云学术

Combining γ‐GT , PIVKA‐II , and AFP to predict long‐term prognosis in patients with hepatocellular carcinoma after hepatectomy

Published:2023-01-24 Issue:4 Volume:50 Page:287-297
ISSN:0305-1870
Container-title:Clinical and Experimental Pharmacology and Physiology
language:en
Short-container-title:Clin Exp Pharma Physio

Author:

Sun Lin¹²^ORCID,Gu Meixiu¹²,Cai Jiabin³,Yang Wenjing¹²,Pan Baishen¹²⁴⁵,Wang Beili¹²⁴⁵,Zhang Chunyan¹²⁴⁵,Guo Wei¹²⁴⁵

Affiliation:

1. Department of Laboratory Medicine Zhongshan Hospital, Fudan University Shanghai China

2. Branch of National Clinical Research Center for Laboratory Medicine Shanghai China

3. Department of Liver Surgery and Transplantation, and Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education) Liver Cancer Institute, Zhongshan Hospital, Fudan University Shanghai China

4. Department of Laboratory Medicine Xiamen Branch, Zhongshan Hospital, Fudan University Xiamen China

5. Department of Laboratory Medicine Wusong Branch, Zhongshan Hospital, Fudan University Shanghai China

Publisher

Wiley

Subject

Physiology (medical),Pharmacology,Physiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1440-1681.13745

Reference39 articles.

1. Cancer incidence, mortality, and burden in China: a time‐trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020

2. Hepatocellular carcinoma

3. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

4. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

5. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma